EFFICIENCY OF BIOFLAVONOID QUERCETIN AND RNA-CONTAINING DRUG SODIUM NUCLEINAT IN COMPLEX TREATMENT OF PATIENTS WITH MYOCARDIAL INFARCTION AND FUNCTIONAL LIVER DISORDERS

Background. The study has shown that functional liver disorders develop in patients with MI, which requires correction.

Material and methods. The study involved 149 patients with acute MI. All examinations were repeated several times on the 1, 14 and 28 day of the treatment.

Results. The patients with functional liver disorders have a higher incidence of epistenocardial pericarditis, arrhythmia and systolic dysfunction. They are characterised by highly activated lipid peroxidation and immunological disorders. A combined therapy with quercetin resulted in improving hemodynamics and reducing the manifestations of liver dysfunction. RNA-containing drug significantly improved the immune status and reduced signs of immuno-inflammatory syndromes.

Conclusions. 1.In patients with MI and functional liver disorders, the primary pathological process is characterised by significant violations of systolic and diastolic function of the heart, more frequent development of complications, activation of lipid peroxidation and secondary immunodeficiency. 2. The inclusion of bioflavonoid quercetin in the treatment of patients with MI helps to restore the antioxidant defence system, improve myocardial contractile function and reduce clinical laboratory manifestations of cytolytic and cholestatic syndromes in patients due to antioxidant and membrane stabilizing properties of the drug. 3. The usage of the RNA-containing drug Nuclex improves immune reactivity, reduces symptoms of expressed mesenchymal-inflammatory and necro-resorptive syndromes in patients with MI and functional liver disorders.